地西他滨联合CAG方案治疗复发难治性急性髓系白血病的临床分析

Clinical Analysis of Decitabine and CAG Scheme in Treatment of Relapsed and Refractory Acute Myeloid Leukemia

目的探讨地西他滨联合CAG方案治疗复发难治性急性髓系白血病(AML)的效果。方法将复发难治性AML患者45例分为两组,对照组实施CAG方案治疗,观察组添加地西他滨联合治疗,分析两组治疗效果。结果观察组治疗缓解率81.8%高于对照组的60.9%,差异具有统计学意义(P<0.05)。观察组不良反应发生率50.0%;对照组不良反应发生率52.2%,差异无统计学意义(P>0.05)。结论地西他滨联合CAG方案治疗复发难治性AML患者效果良好。

Objective To study the effect of decitabine and CAG combination regimen for relapsed and refractory acute myeloid leukemia（AML）. Methods 45 patients with refractory AML recurrence were divided into two groups,control group,the implementation of the CAG regimen for observation group added to west treatment,combination analysis of two groups of therapeutic effect. Results The observation group treatment remission rate 81.8% higher than that of control group 81.8%,significant difference（P 〈 0.05）. Observation group 50.0% incidence of adverse reactions,control group 52.2% incidence of adverse reactions,there was no significant difference（P 〉 0.05）. Conclusion Decitabine and CAG scheme for patients with refractory AML combination effect is good,worthy of clinical promotion.